Search
for
Sort by
Research 181–210 of 1000+
- Targeted delivery of siRNA to human cancer and human embryonic stem cells with cell level resolution
- Survey on adverse events associated with drug therapy for breast cancer patients
- Androgen deprivation therapy may constitute a more effective COVID-19 prophylactic than therapeutic strategy
- Development and Evaluation of a Niosome-Integrated Microneedle System for Targeted Follicular Delivery of Ketoconazole in Alopecia Therapy
- Targeting integrin pathways: mechanisms and advances in therapy
- 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
- Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views
- Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022
- Advances of Microneedles for Cancer Diagnosis and Therapy
- Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
- Causal associations between plasma proteins and prostate cancer: a Proteome-Wide Mendelian Randomization
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
- Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
- MoS2 Nanoclusters-based biomaterials for disease- impaired wound therapy
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- An in-depth study of DOPE:DOPC liposomes to maximize targeted drug delivery to cancer-associated cells
- Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer
- Targeted cell delivery of mesenchymal stem cell therapy for cardiovascular disease applications: a review of preclinical advancements
- Efficacy and safety of dual-targeted therapy for refractory inflammatory bowel disease: a retrospective case series from three tertiary general hospitals in China
- Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers
- Bioorthogonal Catalytic Microneedles Based on a Cytotoxic PEI Matrix for Synergistic Melanoma Therapy
- Molecular Mechanisms and Targeted Therapeutics in Androgenetic Alopecia: From Signaling Pathways to Regenerative Approaches
- Neoadjuvant Therapy with Disitamab Vedotin in Treating Muscle-Invasive Bladder Cancer: A Case Report
- Mucocutaneous Side Effects of Antineoplastic Drugs Used in Cancer Therapy in Erbil
- Advancing Design Strategy of PROTACs for Cancer Therapy
- Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- Cellular senescence in skin‐related research: Targeted signaling pathways and naturally occurring therapeutic agents